THE "NEW" PROSTATE CANCER INFOLINK

Two years after the trial was stopped early (in April 2011), Quinn et al. have published the final results of the randomized, double-blind, placebo-controlled, Phase III trial of atrasentan + docetaxel + prednisone in men with metastatic castration-resistant prostate cancer (mCRPC).

We had reported the early termination of this trial “for futility” at the time. The paper just published in Lancet Oncology clearly confirms the lack of any improvement in effectiveness from the addition of atrasentan (an endothelin-1 receptor antagonist) to standard chemotherapy with docetaxel + prednisone compared to the combination of a placebo + docetaxel + prednisone.

Summary information is also available in a report inThe ASCO Post.

Filed under: Drugs in development, Management, Uncategorized | Tagged: atrasentan, castration-resistant, chemotherapy, mCRPC, metastatic |